The story of copyright's flagship drug presents a complex case for observers in the pharmaceutical sector. While initially a phenomenal success, creating vast sums, the exclusivity lapse and the subsequent flood of generic competitors have drastically affected revenue. This raises questions about the long-term profitability of similar therapeuti… Read More